Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 20;7(5):3431-3440.
doi: 10.1021/acsabm.4c00345. Epub 2024 May 2.

Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity

Daniil Spector  1   2 , Anna Bubley  1 , Anastasia Zharova  1 , Vladislav Bykusov  1 , Dmitry Skvortsov  1 , Daria Ipatova  1 , Alexander Erofeev  2 , Petr Gorelkin  2 , Alexander Vaneev  1   2 , Dmitrii Mazur  1 , Vita Nikitina  1 , Mikhail Melnikov  1 , Vladimir Pergushov  1 , Dmitry Bunin  3 , Vladimir Kuzmin  4 , Alexey Kostyukov  4 , Anton Egorov  4 , Elena Beloglazkina  1 , Roman Akasov  5   6 , Olga Krasnovskaya  1
Affiliations

Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity

Daniil Spector et al. ACS Appl Bio Mater. .

Abstract

Light-induced release of cisplatin from Pt(IV) prodrugs represents a promising approach for precise control over the antiproliferative activity of Pt-based chemotherapeutic drugs. This method has the potential to overcome crucial drawbacks of conventional cisplatin therapy, such as high general toxicity toward healthy organs and tissues. Herein, we report two Pt(IV) prodrugs with BODIPY-based photoactive ligands Pt-1 and Pt-2, which were designed using carbamate and triazole linkers, respectively. Both prodrugs demonstrated the ability to release cisplatin under blue light irradiation without the requirement of an external reducing agent. Dicarboxylated Pt-2 prodrug turned out to be more stable in the dark and more sensitive to light than its monocarbamate Pt-1 counterpart; these observations were explained using DFT calculations. The investigation of the photoreduction mechanism of Pt-1 and Pt-2 prodrugs using DFT modeling and ΔG0 PET estimation suggests that the photoinduced electron transfer from the singlet excited state of the BODIPY axial ligand to the Pt(IV) center is the key step in the light-induced release of cisplatin from the complexes. Cytotoxicity studies demonstrated that both prodrugs were nontoxic in the dark and toxic to MCF-7 cells under low-dose irradiation with blue light, and the observed effect was solely due to the cisplatin release from the Pt(IV) prodrugs. Our research presents an elegant synthetic approach to light-activated Pt(IV) prodrugs and presents findings that may contribute to the future rational design of photoactivatable Pt(IV) prodrugs.

Keywords: BODIPY; PET; cisplatin; photoactivation; prodrug.

PubMed Disclaimer

Similar articles

See all similar articles

Publication types

MeSH terms